ストックスクリーナーアプリを入手
1.37
6.80%
-0.10
アフターアワーズ：
1.37
前日終値:
$1.47
開ける：
$1.41
24時間の取引高:
913.05K
Relative Volume:
1.22
時価総額：
$188.11M
収益：
$42.51M
当期純損益:
$-116.49M
株価収益率:
-1.2232
EPS:
-1.12
ネットキャッシュフロー:
$-120.82M
1週間 パフォーマンス:
-21.26%
1か月 パフォーマンス:
-33.82%
6か月 パフォーマンス:
-82.21%
1年 パフォーマンス:
-82.75%
1日の値動き範囲:
$1.33
$1.50
1週間の範囲:
$1.33
$1.75
52週間の値動き範囲:
$1.33
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
TNGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
1.37 | 188.11M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-17 | 開始されました | Jefferies | Buy |
| 2024-04-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 開始されました | Piper Sandler | Overweight |
| 2023-12-08 | 開始されました | B. Riley Securities | Buy |
| 2022-10-20 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Tango Therapeutics Inc (TNGX) 最新ニュース
Swiss National Bank Raises Stock Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Charles Schwab Investment Management Inc. Acquires 26,192 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Bank of New York Mellon Corp Sells 8,715 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics to Highlight Preclinical Data on - GlobeNewswire
Breakthrough: Novel Brain-Penetrant Cancer Drugs Target Previously Untreatable Tumors - Stock Titan
Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa
Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials - Investing.com
Tango Therapeutics, Inc. (NASDAQ:TNGX) Short Interest Up 18.5% in February - Defense World
Tango Therapeutics executive sells shares worth $43,865 - MSN
Cantor Fitzgerald Issues Negative Forecast for TNGX Earnings - Defense World
Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday - Defense World
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity - MSN
Mesothelioma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough - Simply Wall St
Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint - Yahoo Finance UK
Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks
Tango Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Tango Therapeutics, Inc. SEC 10-K Report - TradingView
Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times
Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Can Tango's Cancer Breakthroughs in Pancreatic and Lung Cancer Outweigh Its Growing Losses? - StockTitan
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter
Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences - The Manila Times
Can Tango's Synthetic Lethality Approach Transform Cancer Treatment? Key Conferences to Watch - StockTitan
Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Declines By 22.5% - MarketBeat
Q3 Earnings Estimate for TNGX Issued By Leerink Partnrs - Armenian Reporter
Analysts Offer Predictions for TNGX Q3 Earnings - MarketBeat
Q1 Earnings Forecast for TNGX Issued By Leerink Partnrs - MarketBeat
Q3 Earnings Forecast for TNGX Issued By Leerink Partnrs - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) CEO Barbara Weber Sells 9,778 Shares - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Daniella Beckman Sells 4,284 Shares - MarketBeat
Adam Crystal Sells 7,432 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock - MarketBeat
Tango Therapeutics Inc (NASDAQ: TNGX): Can A Stock Be -1.94% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel
Tango Therapeutics CEO Barbara Weber sells $57,710 in stock - MSN
One Tango Therapeutics Insider Raised Stake By 400% In Previous Year - Yahoo Finance
What is Leerink Partnrs’ Estimate for TNGX Q1 Earnings? - Defense World
Tango Therapeutics CFO Beckman sells $25,281 in stock - MSN
Tango Therapeutics CFO Beckman sells $25,281 in stock By Investing.com - Investing.com South Africa
Tango Therapeutics CEO Barbara Weber sells $57,710 in stock By Investing.com - Investing.com Australia
Tango Therapeutics executive sells shares worth $43,865 By Investing.com - Investing.com Australia
Tango Therapeutics general counsel Barry Douglas sells $16,369 in stock - MSN
Is Tango Therapeutics Inc (TNGX) worth investing in despite its overvalued state? - US Post News
TNGX’s 2023 Market Dance: Up 8.41% – Time to Invest? - The InvestChronicle
Tango Therapeutics Inc (TNGX) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):